<!DOCTYPE html><html><head><title> Pacifica Code Section 26-18-S105 </title><link rel="stylesheet" href="/assets/style.css"/></head><body>
<b>26-18-105.&nbsp;
          </b><b>Drug prior approval program.</b>
<br>
<a id="26-18-105(1)" name="26-18-105(1)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(1)</td><td style="width:99%">
A drug prior approval program approved or implemented by the board shall meet the following conditions:
<a id="26-18-105(1)(a)" name="26-18-105(1)(a)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(a)</td><td style="width:99%">
except as provided in Subsection <a href="#26-18-105(2)">(2)</a>, a drug may not be placed on prior approval for other than medical reasons;</td>
</tr>
</tbody></table>
<a id="26-18-105(1)(b)" name="26-18-105(1)(b)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(b)</td><td style="width:99%">
the board shall hold a public hearing at least 30 days prior to placing a drug on prior approval;</td>
</tr>
</tbody></table>
<a id="26-18-105(1)(c)" name="26-18-105(1)(c)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(c)</td><td style="width:99%">
notwithstanding the provisions of Section <a href="../../Title52/Chapter4/52-4-S202.html?v=C52-4-S202_2021050520210701">52-4-202</a>, the board shall provide not less than 14 days' notice to the public before holding a public hearing under Subsection <a href="#26-18-105(1)(b)">(1)(b)</a>;</td>
</tr>
</tbody></table>
<a id="26-18-105(1)(d)" name="26-18-105(1)(d)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(d)</td><td style="width:99%">
the board shall consider written and oral comments submitted by interested parties prior to or during the hearing held in accordance with Subsection <a href="#26-18-105(1)(b)">(1)(b)</a>;</td>
</tr>
</tbody></table>
<a id="26-18-105(1)(e)" name="26-18-105(1)(e)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(e)</td><td style="width:99%">
the board shall provide evidence that placing a drug class on prior approval:<a id="26-18-105(1)(e)(i)" name="26-18-105(1)(e)(i)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(i)</td><td style="width:99%">
will not impede quality of recipient care; and</td>
</tr>
</tbody></table>
<a id="26-18-105(1)(e)(ii)" name="26-18-105(1)(e)(ii)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(ii)</td><td style="width:99%">
that the drug class is subject to clinical abuse or misuse;</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<a id="26-18-105(1)(f)" name="26-18-105(1)(f)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(f)</td><td style="width:99%">
the board shall reconsider its decision to place a drug on prior approval:<a id="26-18-105(1)(f)(i)" name="26-18-105(1)(f)(i)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(i)</td><td style="width:99%">
no later than nine months after any drug class is placed on prior approval; and</td>
</tr>
</tbody></table>
<a id="26-18-105(1)(f)(ii)" name="26-18-105(1)(f)(ii)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(ii)</td><td style="width:99%">
at a public hearing with notice as provided in Subsection <a href="#26-18-105(1)(b)">(1)(b)</a>;</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<a id="26-18-105(1)(g)" name="26-18-105(1)(g)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(g)</td><td style="width:99%">
the program shall provide an approval or denial of a request for prior approval:<a id="26-18-105(1)(g)(i)" name="26-18-105(1)(g)(i)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(i)</td><td style="width:99%">
by either:
<a id="26-18-105(1)(g)(i)(A)" name="26-18-105(1)(g)(i)(A)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(A)</td><td style="width:99%">
fax;</td>
</tr>
</tbody></table>
<a id="26-18-105(1)(g)(i)(B)" name="26-18-105(1)(g)(i)(B)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(B)</td><td style="width:99%">
telephone; or</td>
</tr>
</tbody></table>
<a id="26-18-105(1)(g)(i)(C)" name="26-18-105(1)(g)(i)(C)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(C)</td><td style="width:99%">
electronic transmission;</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<a id="26-18-105(1)(g)(ii)" name="26-18-105(1)(g)(ii)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(ii)</td><td style="width:99%">
at least Monday through Friday, except for state holidays; and</td>
</tr>
</tbody></table>
<a id="26-18-105(1)(g)(iii)" name="26-18-105(1)(g)(iii)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(iii)</td><td style="width:99%">
within 24 hours after receipt of the prior approval request;</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<a id="26-18-105(1)(h)" name="26-18-105(1)(h)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(h)</td><td style="width:99%">
the program shall provide for the dispensing of at least a 72-hour supply of the drug on the prior approval program:<a id="26-18-105(1)(h)(i)" name="26-18-105(1)(h)(i)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(i)</td><td style="width:99%">
in an emergency situation; or</td>
</tr>
</tbody></table>
<a id="26-18-105(1)(h)(ii)" name="26-18-105(1)(h)(ii)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(ii)</td><td style="width:99%">
on weekends or state holidays;</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<a id="26-18-105(1)(i)" name="26-18-105(1)(i)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(i)</td><td style="width:99%">
the program may be applied to allow acceptable medical use of a drug on prior approval for appropriate off-label indications; and</td>
</tr>
</tbody></table>
<a id="26-18-105(1)(j)" name="26-18-105(1)(j)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(j)</td><td style="width:99%">
before placing a drug class on the prior approval program, the board shall:<a id="26-18-105(1)(j)(i)" name="26-18-105(1)(j)(i)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(i)</td><td style="width:99%">
determine that the requirements of Subsections <a href="#26-18-105(1)(a)">(1)(a)</a> through <a href="#26-18-105(1)(i)">(i)</a> have been met; and</td>
</tr>
</tbody></table>
<a id="26-18-105(1)(j)(ii)" name="26-18-105(1)(j)(ii)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(ii)</td><td style="width:99%">
by majority vote, place the drug class on prior approval.</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<a id="26-18-105(2)" name="26-18-105(2)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(2)</td><td style="width:99%">
The board may, only after complying with Subsections <a href="#26-18-105(1)(b)">(1)(b)</a> through <a href="#26-18-105(1)(j)">(j)</a>, consider the cost:
<a id="26-18-105(2)(a)" name="26-18-105(2)(a)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(a)</td><td style="width:99%">
of a drug when placing a drug on the prior approval program; and</td>
</tr>
</tbody></table>
<a id="26-18-105(2)(b)" name="26-18-105(2)(b)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(b)</td><td style="width:99%">
associated with including, or excluding a drug from the prior approval process, including:<a id="26-18-105(2)(b)(i)" name="26-18-105(2)(b)(i)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(i)</td><td style="width:99%">
potential side effects associated with a drug; or</td>
</tr>
</tbody></table>
<a id="26-18-105(2)(b)(ii)" name="26-18-105(2)(b)(ii)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(ii)</td><td style="width:99%">
potential hospitalizations or other complications that may occur as a result of a drug's inclusion on the prior approval process.</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<br>
<br>Amended by Chapter <a href="http://le.utah.gov/UtahCode/ChapterLookup.jsp?chap=205&amp;sess=2010GS">205</a>, 2010 General Session<br>
</body></html>